Polycystic Ovarian Syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Intervention group: The intervention group will receive 250 mg capsules of marrubium vulgare plant twice a day for two months.These capsules are made by Mashhad School of Pharmacy.In o
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 35 Years
Inclusion criteria
Inclusion criteria: Have a history of normal puberty Thyroid tests are normal Rotterdam criteria for polycystic ovarian syndrome The patients age is between 18 and 35 years Lack of thyroid disorders, Hyperprolactinemia, Hyper gonadotropic hypogonadism, Premature ovarian failure, Cushing´s syndroms, Congenital Adrenal Hyperplasia, Ovarian and Adrenal neoplasms and failure to develop physical illnesses Absence of pregnancy Lack of recent history of surgical treatment for Polycystic Ovarian Syndrome and treatment for Polycystic Ovarian Syndrome Do not use sex steroids(such as birth control pills, hormone therapy and androgenic drugs) and not use chemical and herbal medicines Do not use cigarettes and hookah
Exclusion criteria
Exclusion criteria: Being pregnant use of sex steroids Suffering from thyroid disorders, hyperprolactinemia, hypergonadotropic hypogonadism, premature ovarian failure, Cushing's syndrome, congenital adrenal hyperplasia, ovarian and adrenal neoplasms, physical illness Having a history of recent treatment for polycystic ovary syndrome Being under 18 years of age or over 35 years of age
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| In all patients, the level of testosterone is measured at the beginning of the visit and after the end of the treatment period. Timepoint: At the begining of the patient´s visit and after the end of the two-month treatment period. Method of measurement: Using blood samples and radioimmunoassay.;In all patients, the level of estradiol is measured at the beginning of the visit and after the end of the treatment period. Timepoint: At the beginning of the visit and after the end of the two-month treatment period. Method of measurement: Using blood samples and radioimmunoassay.;In all patients, the progesterone level is measured at the beginning and after the end of the treatment period. Timepoint: At the beginning of the visit and after the end of the two-month treatment period. Method of measurement: Using blood samples and radioimmunoassay.;In all patients, the amount of cholesterol is measured at the beginning and after the end of the treatment period. Timepoint: At the beginning of the visit and after the end of the two-month treatment period. Method of measurement: Blood sample.;In all patients, the amount of triglyceride is measured at the beginning of the visit and after the end of the treatment period. Timepoint: At the beginning of the visit and after the end of the two-month treatment period. Method of measurement: blood sample.;In all patients, the amount of fasting blood sugar is measured at the beginning of the visit and after the end of the treatment period. Timepoint: At the beginning of the visit and after the end of the two-month treatment period. Method of measurement: blood sample. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in acne progression before and after treatment are evaluated. Timepoint: At the beginning of the patient´s visit and after the end of the two-month treatment period. Method of measurement: Assessment of hirsutism is performed using its own scurvy.;Changes in menstrual irregularities are assessed. Timepoint: At the beginning of the visit and after the end of the two-month treatment period. Method of measurement: By calculating the menstrual cycle.;Changes in body mass index before and after treatment are evaluated. Timepoint: At the beginning of the visit and after the end of the two-month treatment period. Method of measurement: Using the formula for calculating body mass index. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFatemeh Sargazi
Mashhad University of Medical Sciences
Outcome results
None listed